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ABSTRACT
Gene fusions are known to play critical roles in tumor
pathogenesis. Yet, sensitive and specific algorithms
to detect gene fusions in cancer do not currently ex-
ist. In this paper, we present a new statistical algo-
rithm, MACHETE (Mismatched Alignment CHimEra
Tracking Engine), which achieves highly sensitive
and specific detection of gene fusions from RNA-
Seq data, including the highest Positive Predictive
Value (PPV) compared to the current state-of-the-
art, as assessed in simulated data. We show that
the best performing published algorithms either find
large numbers of fusions in negative control data or
suffer from low sensitivity detecting known driving
fusions in gold standard settings, such as EWSR1-
FLI1. As proof of principle that MACHETE discovers
novel gene fusions with high accuracy in vivo, we
mined public data to discover and subsequently PCR
validate novel gene fusions missed by other algo-
rithms in the ovarian cancer cell line OVCAR3. These
results highlight the gains in accuracy achieved by
introducing statistical models into fusion detection,
and pave the way for unbiased discovery of poten-
tially driving and druggable gene fusions in primary
tumors.
INTRODUCTION
Identification of cancer biomarkers is a crucial goal of on-
cology. Gene fusions are excellent tumor-specific biomark-
ers because they are very rarely present in healthy patients,
and thus have the potential to be used for early diagnosis,
as drug targets, and as neoantigens. Detection of oncogenic
fusions can inform efforts to develop targeted therapy and
provide insight into basic cancer biology.
Both the functional importance of gene fusions and how
tumor-specific markers can be leveraged for cancer treat-
ment are well-appreciated in leukemias, where fusions were
first discovered. In leukemias, recurrent gene fusions and
internal tandem duplications are among the most effective
therapeutic targets. For example, the discovery of oncogenic
gene fusions, including BCR-ABL1 in chronicmyelogenous
leukemia (CML) and the FLT3 internal tandem duplication
in acute myelogenous leukemia (AML), have provided crit-
ical insights into pathogenesis and led to important thera-
peutic advances (1,2). Recurrent gene fusions have also been
identified in solid tumors (3,4).
Prior to the advent of next generation sequencing, many
fusions, including those above, were found using cytoge-
netics or clever candidate-based methodologies. Since that
time, a variety of gene fusions have been discovered using
DNA and RNA-Seq (5–7). Next generation sequencing fo-
cused on fusions involving known oncogenes, has enabled
discovery of fusions in a variety of other cancers that can
be targeted with existing drugs, such as FGFR, ALK and
ROS family gene fusions (8–11).
Despite these important discoveries, the unbiased ascer-
tainment of gene fusions fromRNA-Seq data remains a dif-
ficult and unsolved problem.While discovery of some driver
gene fusions described above was aided by algorithms, all
required human-guided filtering and heuristic approaches
to cull fusions from those likely to be artifactual (12–16).
Recent surveys have concluded that no single RNA-Seq
based fusion algorithm has clear dominant performance
and consensus between algorithms is needed to attain speci-
ficity sufficient for clinical application (17,18). This ap-
proach is problematic because systematic false positives
present in multiple algorithms will continue to populate
consensus lists and lack of sensitivity of a single algorithm
can result in rejection of true positives.
For this reason, there is a pressing need for robust algo-
rithms that detect gene fusions with low false positive rates.
Fusion detection algorithms with high false positive rates
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are unfit for use in clinical sequencing applications, as time
and resources make it impractical to manually scrutinize a
list of gene fusion candidates and/or perform secondary
validations (e.g. PCR for the fusion). Further, in clinical
samples, it is often impractical or impossible to perform
secondary tests of predictions from RNA-Seq because the
amount of RNA is limiting or not available.
Another application of a fusion detection algorithm with
a low false positive rate is the mining of thousands of
publicly available RNA-Seq datasets from tumor samples.
These datasets provide an unprecedented opportunity to
discover novel oncogenes, drug targets and gene fusions,
private or recurrent, that may drive cancers, but algorithms
must be trustworthy without secondary validation, because
tumor RNA is not available (19–21).
In this paper, we present MACHETE (Mismatched
Alignment CHimEra Tracking Engine), a novel, sensitive,
and highly specific method to detect fusion RNAs at an-
notated exonic boundaries from RNA-Seq. This method
significantly extends a previous computational framework
we introduced to detect circular and linear RNA splicing
(22). MACHETE includes key computational and statisti-
cal components, leveraging statistical modeling to prioritize
fusion transcripts. It weeds out false positives while retain-
ing the ability to identify known true positives in gold stan-
dard controls, and in several cases, identify fusions missed
by other algorithms.
MACHETE’s empirical p value is a key statistical contri-
bution as it provides a measure allowing researchers to pri-
oritize fusions for clinical and research validation. This is
an innovation absent in other published algorithms which
prioritize potentially oncogenic events by read count, or
by scores that lack an underlying null statistical model. We
have tested MACHETE against STAR-Fusion, SOAPfuse
(23), as well as EricScript, the best performing algorithms as
defined by a recent evaluation (18). We have evaluatedMA-
CHETE on a simulated negative control dataset (18) and a
‘mixed’ dataset which combines the negative control data-
set with simulated reads derived from fusion transcripts.
The data used in (18) were not available, so we used pub-
lished and available simulated data from (24) and the posi-
tive control data used in (18). MACHETE reports far fewer
false positives in negative controls and provides compara-
ble or better detection of true positives in simulated data
and multiple gold standard cell lines.
MATERIALS AND METHODS
Overview of the MACHETE algorithm
The overall workflow of MACHETE is shown in Figure 1.
MACHETE begins by running KNIFE (22), which parses
sequencing reads into categories that align to the genome,
splice junctions, or those that cannot be aligned. Potential
gene fusions are nominated by read pairs where R1 and R2
both map to a KNIFE index, but their coordinates are far-
ther away than a user-defined radius (discordant spanning
reads), or based on split-read alignment to the genome. Un-
aligned reads are mapped to the nominated fusions, and
MACHETE uses reads that other fusion detection algo-
rithms discard (Figure 2) to model artifactual fusions and
assign a statistical score to each fusion candidate (Figure 3).
The computational steps that precede assignment of statis-
tical scores are important (see Materials andMethods), but
MACHETE’s significant advance is due to its use of statis-
tical models described below. Note that the algorithm does
not depend on read length.
Splice events and fusions reported by MACHETE
Prior to running MACHETE, data is trimmed and pro-
cessed by KNIFE (22), an algorithm designed to find map-
pings to the genome as well as circular and linear splicing
or gene fusions between all pairs of annotated exons within
a sliding 1 megabase (Mb) window. While KNIFE’s main
motivation is detection of circular RNA (25), certain types
of gene fusions, internal tandem duplications (ITDs) and
readthroughs can also be detected byKNIFE (4,21,26). For
this reason, MACHETE output includes KNIFE output,
reported as separate files, for users interested in detecting
local genomic rearrangements or circular RNAs.
In this paper, we focus on the major innovations of MA-
CHETE that enable identification of the following events
not detected by KNIFE: (a) splicing between annotated ex-
ons on the same chromosome separated by more than a
user-defined radius, most likely arising from tandem dupli-
cations or large deletions; (b) inversions, which are defined
as transcripts containing annotated exons separated by the
same user-defined radius or more on the same chromosome
in discrepant transcriptional orientations; and (c) translo-
cations, which are defined as transcripts containing anno-
tated exons from two genes on different chromosomes in the
reference genome. In this paper we call all of these events
‘fusions’. We have used hg19 and the UCSC GRCh37 gene
annotations, but the choice of organism, genome build, an-
notation, and the user-defined radius for detecting events
(a) or (b) are choices which can easily be modified by the
user.
A candidate fusion database from discordant spanning reads
MACHETE uses alignment of paired-end RNA seq reads
output from KNIFE to generate a database of candidate
fusions defined by their diagnostic exon–exon junctions.
Reads where mates R1 andR2were identified byKNIFE as
both aligned to the genome index, both aligned to the lin-
ear junction index, or one mate aligned to the linear junc-
tion index and the other to the genome index, are evaluated
and recorded as ‘discordant’ if mates aligned more than
the user-defined radius apart or on different chromosomes.
These discordant reads signal that there may be a fusion
junction nearby. For each discordant read pair,MACHETE
defines a pair of 20 kb windows in the genome surrounding
R1 and R2 and identifies all exons with a 5′ or 3′ boundary
within these windows. For each exon in the first window and
each in the second, MACHETE adds this exon-exon junc-
tion sequence to a nominated fusion database. Similar logic
is appliedwhen one or both readmatesmap to an annotated
linear exon-exon junction (see Materials and Methods).
A candidate fusion database from split-reads
MACHETE uses split reads to generate a nominated fu-
sion database supplementing the one generated by discor-
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Figure 1. MACHETE workflow.MACHETE takes as input the output of KNIFE (21) and generates a list of nominated fusions using spanning reads (red
path) or split-reads (blue path). Next, reads that failed to align to any of the reference indices in KNIFE are aligned to the database of nominated fusions.
MACHETE statistical models use per-read alignment features and implement an unbiased assessment of the likelihood that a fusion is an artifact due to
sequence homology. These models are applied to produce a fusion report prioritized by statistical scores and read counts.
Figure 2. MACHETE does not censor reads. In the alignment step to the nominated fusion database, MACHETE uses all reads that aligned to a fusion
to assign a statistical score. GAPDH-HFM1 is given as an example of an artifactual fusion. Reads aligning to the fusion are aggregated and used in model
building and generation of a final statistical score for the fusion in the database even if they have low mapping quality, contain mismatches (depicted with
X) or have a small junction overlap. In other algorithms, reads are first censored so that only reads with few mismatches and high overlap are reported,
presenting only positive data on the junction even if the junction is an artifact.
dant spanning reads above. Unlike other algorithms that
identify split reads using dynamic programming (27), MA-
CHETEuses a static definition of a split read as a previously
unaligned read whose first and last user defined number of
nucleotides (nt) map far from one another in the genome
index.
The mapping location of the 5′ and 3′ piece of each split
read are each assigned to the nearest 50 nt bin and the
combination of both bins is termed a bin-pair. If multiple
reads share the same bin-pair, they are grouped to build
a consensus sequence using majority voting to mask po-
tential sequencing errors (see Methods and Supplemental
Figure S1). If this consensus sequence is consistent with an
annotated exon-exon junction, it is nominated as a fusion
junction. If it is not, the consensus is still included in the
split-read fusion database, but will not be included in the
fusion report. Reads used to construct fusion junction se-
quences are considered training data and are excluded from
the unaligned reads that are subsequently aligned to the
nominated fusion database. This leads to a conscientious
underestimation of the abundance of fusions nominated by
split-reads, but allows a disciplined framework for statisti-
cal modeling of the fusions by separating reads used to fit
and test expression of junctions, described below.
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Figure 3. Artifact modeling. (A) Each constructed fusion sequence is aligned to reference indices. Fusions that align to a KNIFE reference index are likely
artifacts due to sequence homology (mappable fusions). Fusions are flagged as split mappable fusions and not reported by MACHETE if the first and
last 40 bases of each fusion sequence, when treated as pseudo paired end reads, align to the reference genome within a 50 kb window of each other. (B)
Unaligned reads are mapped back to putative fusions. If R1 maps across the fusion boundary, the mapping location of R2 can either support that the
pair maps consistently (top left) or not (top right). Alternatively, R1 may align to an indel fusion, which MACHETE considers as evidence against the
fusion being expressed since this could represent a ligation artifact. Each read is assigned a probability, pˆ, of being generated from an expressed fusion
by the GLM. The reported probabilities for reads providing evidence against the fusion are down-weighted. All junctions are assigned a statistical score
based on the aggregated per-read probabilities, termed junction cdf, reflecting the probability that a fusion is an artifact under a model of simple random
sampling of reads. Mappable fusions are used to model the distribution of junction cdf scores for fusions that are artifacts. All fusions that are not flagged
as mappable or split mappable are referred to this distribution and assigned an empirical p value, interpreted as the probability of observing as high a
junction cdf as observed under the null hypothesis that the fusion is an artifact.
A junction database to model confounding biochemical arti-
facts
A critical component of MACHETE is a statistical model
of several types of artifacts that can introduce false positives
into fusion discovery: ligation artifacts, where two cDNAs
from different RNA molecules are ligated (28), and reverse
transcriptase (RT) template switching artifacts, where an
RT enzyme initiates on one RNAmolecule, dissociates and
then re-initiates on a second molecule (29). These artifacts
appear at non-trivial rates during library preparation and
produce what appears to be a sequence compatible with a
fusion transcript. An innovation ofMACHETE is to model
the rate of chimeric artifacts for each candidate fusion junc-
tion in our database via a realistic simplifying assumption
that a read which is a chimeric artifact due to either of these
biochemical events is equally likely to have a spurious fusion
breakpoint at any point along the transcript and should not
be biased to occurring at an exon–exon boundary. Tomodel
this, for each fusion junction, we create indel fusion junc-
tions with symmetric addition and deletion of nucleotides
at the exon-exon junction, which we call the indel fusion in-
dex.
Classification of read pairs
After building a fusion index from either spanning or split
reads, MACHETE maps reads classified as ‘unaligned’ by
KNIFE to the original and indel fusion indices. In cases
where a read aligns to multiple fusions, the read is deter-
mined to align to the fusion with the best alignment score.
The alignment of the mate of this read is determined using
similar priority rules. Based on relative position of align-
ments and their orientation, each read is determined to be
consistent or inconsistent with being generated from the fu-
sion junction to which it aligns. Consistent and inconsis-
tent reads are used differently in downstream steps of MA-
CHETE.
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Prioritizing fusions using statistical scores
The major novelty in MACHETE is its use of statistical
scores to prioritize fusions based on their likelihood of be-
ing false positives. One source of false positives is biochem-
ical artifact. In addition, sequencing errors convolved with
degenerate sequence motifs at exon boundaries can result in
identification of false positive junctional sequences (22,30).
Bona fide mutations or indels in the cancer genome com-
pound this problem and further contribute to artifacts.
One approach to address this problem is to exclude reads
that align to fusions below a certain quality of alignment
score or that contain fewer than a certain number of nu-
cleotides overlapping the fusion junction (Figure 2). This
procedure is called censoring, and to our knowledge, is used
by all fusion detection algorithms. Censoring approaches
result in increasing numbers of artifactual fusions being
reported as sequencing depth increases, especially among
highly expressed genes, due to the convolution of sequenc-
ing errors and sequence homology. If enough reads are se-
quenced, random errors will eventually result in reads that
map to a fusion even if the fusion sequence doesn’t exist in
the input RNA.
MACHETE uses a different approach. Rather than ap-
plying hard thresholds to reads that other algorithms would
have discarded, MACHETE uses these reads to estimate
the probability that each putative fusion is an artifact. The
first step in this process uses the information from all reads
aligning to a fusion junction, including those with poor
alignment scores, reads mapping to the constructed indel
indices, and reads where mates map inconsistently (anoma-
lies). MACHETE fits a generalized linear model (GLM) for
each read, with predictors being alignment scores, mapping
quality, and the amount of junction overlap. The GLM is
used to estimate the probability, p, that the read’s alignment
to a putative fusion was due to an artifact.
The per-read probabilities estimated by the GLM are
aggregated to generate a cumulative score for each nomi-
nated fusion, which is compared to a null distribution.MA-
CHETE constructs a null distribution for each value of N,
the number of reads aligning to the fusion junction, by ran-
domly sampling from the empirical distribution of p for all
reads in the sequencing library whenN is small, and uses the
Hoeffding combinatorial central limit theorem to estimate
this distribution for largeN (31). Comparing the cumulative
score for each junction to the null distribution results in as-
signment of what we deem the junction cdf value to each
fusion junction (see Materials and Methods). Note that all
modeling above is done within a single dataset, the same
dataset that reports putative fusions. No external ontologies
or external control data are needed or used byMACHETE;
themodel is fit separately and independently each timeMA-
CHETE is called using the dataset on whichMACHETE is
run (see Materials and Methods).
Final statistical scoring: including empirical p value assign-
ment
MACHETE uses a statistical framework to generate an em-
pirical p value for each junction, the algorithm’s estimated
probability that the junction with a given score is an arti-
fact based on an empirical null. This value is conceptually
different from the junction cdf score because it uses a more
realistic null model, accounting for structure in the null dis-
tribution lost by simple random sampling of reads that gen-
erates the junction cdf (32). Like other components inMA-
CHETE, the empirical p value is determined by using data
that would have otherwise been discarded. In this case,MA-
CHETE models the null distribution of junction cdf scores
using junctions which bioinformatic evidence supports be-
ing artifacts because they map to the genome or transcrip-
tome (‘mappable fusions’, see Figure 3A andMethods). The
empirical p value for each fusion junction is estimated by re-
ferring its junction cdf to the empirical distribution of junc-
tion cdf scores of mappable fusions. The empirical p value
and junction cdf can be used to determine which fusions
are reported by MACHETE and to prioritize fusions for
follow-up study. Additionally, standard statistical analysis
of these p values could be applied to estimate a false dis-
covery rate (FDR) (33). See Materials and Methods for the
statistical thresholds applied in this paper, which were uni-
form for all samples analyzed. This is a key point because
it means that (a) better results could be obtained by ma-
nipulating cut-offs on a sample-specific basis; and (b) the
thresholds used in this paper are robust and dependable, in
the sense that they can be used to obtain similar results on
any dataset.
Fetal tissue samples
Ribosomal RNA-depleted (rRNA-) total RNA from fetal
tissue samples previously obtained as documented in (22)
were analyzed. 43 samples collected within 1 h of pregnancy
termination at the following gestational ages were obtained
from the following tissues: five adrenal (10.3–20.6 weeks),
one brain (20.6 weeks), seven heart (10.4–20.3 weeks), seven
intestine (10.3–20.6 weeks), three kidney (10.3–20.0 weeks),
six lung (10.2–20.0weeks), seven stomach (10.3–20.6weeks)
and seven liver (10.3–20.6 weeks).
Normal breast epithelial organoids
Raw fastq files generated from samples of three distinct
normal breast epithelial organoids were downloaded on
3 February 2016 from SRA: SRR1027188, SRR1027189,
SRR1027190 (34). Samples contained rRNA– RNA.
Human simulated data
Fastq files from two simulated human paired-end RNA-
Seq experiments, generated as described in (24), were down-
loaded on 6 January 2015 from: http://www.ebi.ac.uk/
arrayexpress/experiments/E-MTAB-1728/files/.
Briefly, transcripts were randomly selected from 11 an-
notation tracks in the UCSCGenome Browser, the original
transcript and novel isoforms generated from the transcript
were included, and expression levels were derived from a
normal human retina RNA-Seq data set. The second sim-
ulated dataset contained more noise than the first. Substi-
tution variants and indel polymorphisms were introduced
into both simulated transcriptomes.
Positive control data from fusionmap was downloaded
from http://www.arrayserver.com/wiki/index.php?title=
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FusionMap. This data was combined with “simulation 1”
from (24) and is referred to as “mixed” data, following the
nomenclature in (18).
CML K562 cell lines
Two replicates containing ribo-depleted and poly-
adenylated (rRNA–/polyA+) RNA from Cold Spring
Harbor Laboratories (CSHL) were downloaded from
ENCODE: https://www.encodeproject.org/experiments/
ENCSR000CPS/ on 31 August 2015. ENCODE acces-
sion ids: sample 1: library ENCLB555ALY (fastq files
ENCFF000HOC and ENCFF000HOE) and sample 2:
library ENCLB555ALX (fastq files ENCFF000HOD and
ENCFF000HOQ).
A total of nine replicates from two biosamples
from UConn were downloaded on 6 April 2016 from
SRA under accession number SRP013565. From EN-
CODE biosample ENCBS087RNA: SRR3192411,
SRR3192412, SRR3192417. From ENCODE Biosam-
ple ENCBS088RNA: SRR3192409, SRR3192410,
SRR3192413, SRR3192415, SRR3192416, SRR3192422.
Samples contained rRNA–/polyA+ RNA.
Ewing’s sarcoma cell lines
Raw fastq files were downloaded on 12 February 2016 from
SRAunder accession number SRP048562. Six samples with
EWS-FLI1 translocations from 2 different cell lines from
(25) were used in the analysis. The EWS-FLI1 fusion was
depleted in some samples by transfection with lentiviral
shRNA shFLI1 and other samples were treated with a con-
trol shGFP which did not deplete the fusion. SRR1594020-
SRR1594023 were obtained from Ewing sarcoma cell line
SKMNC. SRR1594020 and SRR1594022 were treated with
shGFP for 48 and 96 h, respectively. SRR1594021 and
SRR1594023 were treated with shFLI1 for 48 and 96 h,
respectively. SRR1594024 and SRR1594025 were obtained
from Ewing sarcoma cell line A673. The former was treated
with shGFP for 48 h. The latter was treated with shFLI1 for
48 h. Samples contained rRNA–/polyA+ RNA.
Ovarian cancer cell lines
Raw fastq files were downloaded on 18 March 2016
from SRA. SRR1772257 (rRNA–/RNase-R+) and
SRR1772957 (rRNA–) were obtained from the OVCAR3
cell line.
Data preprocessing
Raw fastq files were processed using default settings
of TrimGalore version 0.3.7: http://www.bioinformatics.
babraham.ac.uk/projects/trim galore/ and Cutadapt ver-
sion 1.5 (35) and these trimmed files were used as input to
SOAPfuse, STAR-Fusion, and KNIFE which yielded MA-
CHETE input files.
SOAPfuse, EricScript and STAR-Fusion
SOAPfuse (v1.27) and STAR-Fusion (version 0.7.0) indices
were built using the human reference genome hg19. In ad-
dition to the trimmed fastq files, SOAPfuse uses an addi-
tional sample file which was generated dynamically with a
custom PERL script. Since both STAR-Fusion and SOAP-
fuse were designed specifically for fusion detection, we ran
all samples with the suggested parameters provided by the
authors: http://soap.genomics.org.cn/soapfuse.html https://
github.com/STAR-Fusion/STAR-Fusion/wiki
We used the following output files: for STAR-Fusion:
*star-fusion.fusion candidates.final.abridged; for SOAP-
fuse: *final.Fusion.specific.for.trans
We used filtered results from EricScript 0.5.5 Ensemble
version 73 per the user manual from: https://sites.google.
com/site/bioericscript/download
Analysis of MACHETE versus SOAPfuse, EricScript and
STAR-Fusion
Filtered results for each of the algorithm are available
as supplemental tables and scripts. MACHETE source
code is available through the Salzman lab website (http:
//salzmanlab.stanford.edu/software/).
PCR Validation in OVCAR3
RNA was extracted and reverse transcribed using standard
protocols. All PCRs were performed for 35 cycles, 30 s ex-
tension times using TaqSupermix and the following PCR
primers. PCR products were TOPO cloned and Sanger se-
quencing was performed according to standard protocols.
Benchmarking against SOAPfuse, EricScript and STAR-
Fusion
We have benchmarkedMACHETE against SOAPfuse (23),
EricScript (36) and STAR-Fusion (27). SOAPfuse achieved
the best balance between sensitivity and specificity accord-
ing to recent independent benchmarks (18,32); EricScript
was the top performer according to analyses performed in
(18). On some samples, STAR-Fusion performed better in
our hands than SOAPfuse or EricScript, so we included it
in our analysis. We have analyzed these algorithms on pub-
licly available data for three cancer types: (i) two indepen-
dent datasets from the BCR-ABL1 positive cell line K562,
(ii) data from two Ewing’s sarcoma cell lines and (iii) the
ovarian cancer cell line OVCAR3. We also analyzed these
algorithms on three negative control datasets: (i) 43 samples
from 8 normal human fetal tissue types, (ii) three normal
breast organoids and (iii) two datasets simulated from the
human reference transcriptome under two different param-
eter regimes (24); (iv) a mixed dataset that is comprised of
negative control data and simulated positive control fusions
as described in (18).
Criteria for benchmarking and algorithm comparison
The vast majority of validated gene fusions, including the
BCR-ABL1 and EWS-FLI1 fusions discussed in this paper,
occur at exon–exon boundaries (37). MACHETE only de-
tects fusions at exon boundaries, and these stringent criteria
improve specificity of other algorithms by eliminating some
false positive fusions in normal samples. In order to directly
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compare the results of fusion algorithms, we imposed a uni-
form set of filtering criteria on the results of all algorithms
that (i) fusions must be reported at annotated exon–exon
boundaries, and (ii) candidate fusion junctions on the same
chromosome and on the same strand have to occur more
than 1Mb apart or be inversions>100 kb apart. The reason
for imposing a different radius on junctions between exons
on the same strand is to prevent circular RNA from being
reported as a fusion, since it is typically detected between
exons within 1 Mb of the genome. MACHETE results are
additionally filtered based on statistical scores which are not
provided by other algorithms, except EricScript (see Mate-
rials and Methods). To assess the effect of imposing a com-
monly used threshold of more than one read on the false
positive rate for all algorithms, we compared results using
either all junctions fulfilling the above criteria, or the subset
of those junctions with more than one mapping read. For
the remainder of the paper we report the number of distinct
fusions found by an algorithm in each sample or sample
type in the form of ‘Q|R’ where Q and R are the filtered
count without and with using the read count threshold of
1, respectively.
RESULTS
MACHETE significantly improves specificity on negative
controls
In evaluating specificity, we adopted standards previously
applied by third party assessments of fusion detection al-
gorithms (38). Namely, a fusion detection algorithm with
high specificity should find no fusions in data simulated
from the reference human transcriptome. In normal sam-
ples, the algorithm should also rarely, if ever, find inter-
chromosomal fusions, with exceptions occurring only when
cryptic translocations have occurred. Because such events
are thought to be exceptionally rare, we assume that in-
terchromosomal fusions reported by algorithms in normal
samples are artifacts, as other authors have done (39). A
subset of individuals harbor local tandem duplications in
their genomes, copy number variants (CNVs), that could
in principle interrupt protein coding genes and result in
gene fusions. However, these events are also considered to
be rarely detected in normal cells, especially between exons
separated by more than 1Mb (40,41), motivating our filter-
ing criteria introduced above.
Using the same statistical thresholds that give high true
positive rates in the cancer samples, MACHETE has an
unprecedented low false positive rate, reporting only one
false positive fusion among all of the negative controls. This
is a significant advance over SOAPfuse and STAR-Fusion
which each report large numbers of distinct fusions in the
same samples. Figure 4A depicts the number of fusion iso-
forms detected byMACHETE and other algorithms in neg-
ative control data. In the simulated data, MACHETE and
STAR-Fusion reported only three fusions, all of which were
TOP3B-PI4KA isoforms that were included in the simu-
lated ground truth (true positives) (24) . SOAPfuse found
one of the three fusions, but reported an additional 7|5 fu-
sions that were not in the simulated data; similarly, Eric-
script had 23|23 fusions that were absent from the simula-
tion, evidence of reporting significant numbers of false pos-
itives.
In normal fetal RNA, MACHETE reported no fusions
in 43 samples. In the same data, SOAPfuse reported 5|2
fusions, while STAR-Fusion reported 39|32 fusions and
Eriscript reported 56|54 In normal breast organoids, SOAP-
fuse detected 11|4 fusion isoforms and STAR-Fusion de-
tected 45|15 fusions and EricScript reported 37|35. In the
same data, MACHETE reported a single potential fusion,
MBNL2-GNAS, which was also reported by SOAPfuse.
While STAR-Fusion matched the specificity of MA-
CHETE on simulated data, it reported many more pre-
sumed false positives thanMACHETEor SOAPfuse in nor-
mal samples; EricScript had similar numbers of presumed
false positives. These results underline the significant im-
provement in specificity achieved by MACHETE on both
real and simulated data.
MACHETE improves positive predictive value compared to
current best performing algorithms
We blindly assessed the sensitivity and Positive Predictive
Value (PPV) = TP/(FP + TP) of MACHETE compared
to the top performing algorithms from (18) and (42) in a
context where the ground truth is known. Because we were
not able to obtain the negative control simulated data used
in (18), we used third party simulated data from the neg-
ative control of Engstrom simulation 1 in (24) that lacked
any gene fusions as our negative control data, and concate-
nated all reads from the positive control dataset containing
50 gene fusions used in (18). In order to have uniform read
lengths, the 3′ most base of the reads from the Engstrom
simulation 1 was removed from each read. We refer to this
as the ’mixed’ dataset.
MACHETE reported 33 of the 50 true positive fusions
and 0 false positives, a sensitivity of 66% and a PPV of
100%. In contrast, the best performing algorithms from
(18), EricScript (resp. SOAPfuse and STAR-Fusion) had
sensitivity of 80% (74% and 84%) and PPV of 77% (71%
and 91%). STAR-Fusion performs well here, having a PPV
close to MACHETE. However, as discussed below, STAR-
Fusion suffers from a very high FP rate in other samples,
while MACHETE maintains tight control of FPs (see Fig-
ure 5).
The use of statistical scores by MACHETE is key to its
precision and high PPV. MACHETE detects the sequences
of 42 fusions in the ground truth set of fusions, but nine of
them are removed based on their poor statistical scores. We
display the distribution of empirical p values in Figure 5B
stratified bywhether the fusion is a TP. Figure 5B shows that
all fusionswith low empirical p values and high junction cdf
scores are true positives which is why statistical scoring al-
lows MACHETE to achieve a perfect PPV on the blinded,
third-party-generated mixed dataset. These features are not
true of the EricScore, see Figure 5C: even at a high thresh-
old for the EricScore, the PPV is low: at a threshold for the
score of 0.95, 31 TP and 8 FP are reported. MACHETE
achieves higher sensitivity (39 fusions detected) and a PPV
of 1 (0 FP detected). Finally, we note that MACHETE de-
tects 42 fusions, the same sensitivity of STAR-Fusion, but
assigns some TP scores consistent with them being artifacts.
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Figure 4. Performance of MACHETE compared to SOAPfuse, EricScript and STAR-Fusion. (A) Counts of false positive fusions from MACHETE,
SOAPfuse and STAR-Fusion are shown for each of the three types of normal samples used as negative controls in this study. Light blue indicates fusions
supported by a single read, dark blue indicates fusions supported by at least two reads. (B) Isoforms of the EWSR1-FLI (rows 1–4) and FLI-EWSR1
(rows 5 and 6) detected by MACHETE (yellow), STAR-Fusion (green), SOAPfuse (red) and EricScript (blue) in two distinct Ewing’s sarcoma cell lines.
Isoforms 1–3 are detected in both cell lines, 4–6 are only detected in A673 cells. Left panel: SKMNC cells under four treatments. Right panel: A673 cells
under two treatments. Read counts supporting each isoform are shown in white. shRNA treatments are abbreviated as follows; shGFP (48 h): control
treated with shGFP for 48 h; shGFP (96h): control treated with shGFP for 96 h; shFLI1 (48h): cells treated with shFLI1 for 48 h, partially deplet-
ing EWSR1-FLI; shFLI1 (96 h): cells treated with shFLI1 for 96 h, with more extreme, but incomplete, depletion of EWSR1-FLI isoforms. Isoform 1:
EWSR1-FLI1 chr11:128675261-chr22:29683123; Isoform 2: EWSR1-FLI1 chr11:128675261-chr22:29684775; Isoform 3: EWSR1-FLI1 chr22:29683123-
chr11:128677075; Isoform 4: EWSR1-FLI1 chr22:29683123-chr11:128679052; Isoform 5: FLI1-EWSR1 chr11:128651918-chr22:29684595; Isoform 6:
FLI1-EWSR1 chr11:128651918-chr22:29688126
This behavior is predicted for any statistic used to test a hy-
pothesis, and reflects the property that no statistical test (or
statistical algorithm) can have perfect power (i.e. a power of
1).
MACHETE has comparable detection efficiency of BCR-
ABL1 to other algorithms
Increased specificity can always be achieved by shrinking
a rejection region, which would correspond to more strin-
gent thresholds imposed to accept a nominated fusion. To
address the concern that our low false negative rate could
result in decreased statistical power to detect true positives,
we performed tests of MACHETE’s ability to identify pos-
itive control fusions.
We used data from the chronic myelogenous leukemia
(CML) cell line K562 to test for one of the best charac-
terized gene fusions, BCR-ABL1, and another validated
fusion, NUP214-XKR3 (19). A total of 11 replicates gen-
erated in two labs in the ENCODE consortium were an-
alyzed (see Methods). MACHETE, SOAPfuse, EricScript
and STAR-Fusion were run on all 11 replicates, although
SOAPfuse failed to complete after running for seven days
for one sample (SRR3192422) despite repeated attempts.
Across all samples, the algorithms detected only one iso-
form of each of the validated fusions, BCR-ABL1 and
NUP214-XKR3. Within each replicate, these fusions were
within the top three results when ranked by read count for
each algorithm and were consistently the top two results for
MACHETE. Read count filtering did not change detection
of these well-documented fusions. NUP214-XKR3 was de-
tected in all replicates and the BCR-ABL1 fusion was iden-
tified in all replicates except SRR192416 and SRR192417
byMACHETE, SOAPfuse and STAR-Fusion (Supplemen-
tary Tables S2–S5).
Although SRR3192422 was excluded from the above
analysis because SOAPfuse failed to complete, we examined
the fusions reported by MACHETE and STAR-Fusion in
this replicate (Supplementary Tables S2 and S4). Both al-
gorithms reported more fusions than in any of the other
10 replicates: 247|154 for STAR-Fusion and 57|46 for MA-
CHETE. BCR-ABL1 and NUP214-XKR3 remained the
fusions with the highest read counts reported by MA-
CHETE in this replicate. NUP214-XKR3 remains the top
result for STAR-Fusion, but the algorithm reported 35
other fusions with as many or more reads as BCR-ABL1 in
this replicate. These results demonstrate MACHETE’s abil-
ity to prioritize true positive fusions even in samples that
are problematic for other algorithms.
MACHETE improves in vivo sensitivity of fusion detection in
Ewing’s sarcoma cell lines
Ewing’s sarcoma is characterized by a translocation result-
ing in expression of fusion transcripts between the EWSR1
gene on chromosome 22 and the FLI1 gene on chro-
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Figure 5. Sensitivity analysis and statistical properties ofMACHETE versus EricScript, SOAPfuse, and STAR-Fusion. PanelA: Comparison of sensitivity
and PPV of top fusion algorithms. MACHETE has highest PPV driven by its use of statistical scores (see B) and lower sensitivity than other algorithms
which detect many FP in some or all control data sets. Panel B: MACHETE uses the empirical p value (<0.1) and junction cdf score (>0.2), thresholds
chosen before testing MACHETE on mixed data, and blindly achieves sensitive separation of TP and FP (boxed area). Panel C: Ericscore distributions
among FP and TP are similar, showing this score does not discriminate TP and FP.
mosome 11 (11,22). We evaluated the sensitivity of MA-
CHETE’s detection of the documented alternative splicing
between EWSR1 and FLI1 in the Ewing’s sarcoma cell lines
SKMNC and A673, as well as the detection of the recipro-
cal fusion event between FLI1 and EWSR1 in A673 (43)
(Figure 4B).
We analyzed RNA-Seq data generated from two experi-
ments using the cell line A673 and four experiments using
the cell line SKMNC (44). shRNA against FLI1, target-
ing the EWSR1-FLI1 fusion, and negative control shRNA
against GFP were introduced including four SKMNC sam-
ples: treatment of shGFP for 48 h, shGFP for 96 h, shFLI1
for 48 h, or shFLI1 for 96 h. The two A673 samples con-
sisted of the following experiments: treatment of shGFP for
48 h or shFLI1 for 96 h. Because shRNA modulated the
expression of the EWSR1-FLI1 transcripts, this dataset al-
lowed us to assess the sensitivity of detection of EWSR1-
FLI1.
MACHETE, EricScript and STAR-Fusion detected the
expression of EWSR1-FLI1 fusion transcripts in each of the
six samples although EricScript failed to detect isoform 2, 3
or 4 (see Figure 4). MACHETE detected more isoforms of
EWSR1-FLI1 than other algorithms while reporting fewer
overall fusions: STAR-Fusion (resp. EricScript) reports 78
(resp. 60) distinct fusion isoforms across all six samples,
from which it would be difficult to select fusions for valida-
tion MACHETE reports only 16 distinct expressed fusion
isoforms, including one FLI1-EWSR1 and four distinct
EWSR1-FLI1 isoforms. SOAPfuse also reports 16 distinct
fusion isoforms, although only two of these are EWSR1-
FLI isoforms and none are FLI-EWSR1.
The A673 sample is known to express the reciprocal
FLI1-EWSR1 transcript (43). SOAPfuse did not detect any
fusion transcripts derived from the reciprocal translocation.
MACHETE detected one isoform of FLI1-EWSR1 and Er-
icScript had the best sensitivity for this isoform. Together,
this data demonstrates that MACHETE is more sensitive
and specific than the other algorithms in the analyzed Ew-
ing’s sarcoma data.
MACHETE discovers novel fusions in ovarian cancer cell line
OVCAR3
All algorithms were used to predict fusions in publicly avail-
able RNA-Seq data from the ovarian cancer cell line OV-
CAR3. We used RT-PCR on RNA we extracted in our
own lab to validate the most abundant predicted fusions
that passed MACHETE’s statistical filters: two splice iso-
forms of a translocation giving rise to a fusion between the
genes SPEN and NEU1, another translocation resulting in
a fusion between NUP98 and the gene BEAN1, and a >2
Mb predicted duplication resulting in a fusion between the
genes ITSN2 and OTOF. All three fusions, including the
predicted splice variant in SPEN-NEU1 were validated (see
Materials and Methods).
EricScript predicted NUP98-BEAN1 in both samples
from OVCAR3, but it did not detect any of the isoforms
of the SPEN-NEU1 fusion, and predicted ITSN2-OTOF
in only one of two samples. SOAPfuse predicted only one
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fusion in each of the two OVCAR3 samples with one read
each: in one sample, the fusion LINC00665-HKR1, and in
the other, SPEN-NEU1. STAR-Fusion detected 27|17 fu-
sions, but failed to detect either of the two SPEN-NEU1
isoforms that were predicted by MACHETE and validated
by PCR underlining in vivo gains in sensitivity contributed
by MACHETE.
DISCUSSION
In this paper, we describe a new statistical framework for
detecting and quantifying gene fusions. The bioinformatic
methodology is transparent and makes no ad hoc or heuris-
tic choice. This allows MACHETE to achieve highly spe-
cific and sensitive unsupervised detection of fusions. Sta-
tistical models are the workhorse of MACHETE, and al-
low it to achieve an essentially null background on cyto-
genetically normal samples, which, to our knowledge, has
not been achieved by other published fusion detection al-
gorithms. This feature is an innovation of MACHETE that
uniquely situates it for application in cancer diagnosis and
discovery of driving and targetable gene fusions.
While achieving specificity, MACHETE is still able to
identify true positives at a similar or improved rate com-
pared to current top algorithms; noteworthy cases of im-
proved sensitivity for fusions in the OVCAR3 cell line. In
other cases, such as the Ewing’s sarcoma data, MACHETE
and STAR-Fusion have similarly high sensitivity, but MA-
CHETE is muchmore specific. The extremely low false pos-
itive rate achieved byMACHETE, demonstrated by its per-
formance in normal samples, allows it to discriminate lowly
expressed but potentially biologically important gene fu-
sions from false positives regardless of their expression lev-
els. For example, NUP98 is known to be a recurrently fused
oncogene (45) and was first identified in AML (46). To our
knowledge, this is the first report and validation of aNUP98
fusion in an ovarian cancer cell line.
MACHETE’s assignment of a statistical score, including
an empirical p value, to each putative fusion, allows for un-
supervised detection of fusions. This has important impli-
cations for research and for deploying MACHETE to an-
alyze large public datasets. Algorithms that require human
guidance and heuristic filtering are too resource intensive
for these applications, and introduce biases. High false pos-
itives in these algorithms also dilute the statistical signal of
fusions that may yield insight into tumor biology.
Furthermore, fusions can be powerful biomarkers, but
may have low abundance especially if they are to be de-
tected in bodily fluid containing RNA from normal cells.
Thus, for clinical use, comparatively lowly expressed fusions
would have to be detected in a background of abundant
RNA from normal cells. In addition, clinical applications
cannot support secondary validation, as described in the
introduction. Thus, the high specificity and sensitivity of
MACHETE promises to improve discovery of significant
fusions in clinical samples.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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